Stock Price & Analysis

The S1 support level for CALC Stock is $2.39 ,The R1 resistant level for CALC Stock is $3.04.

As of the end of day on 2025-02-05, the price of CALC Stock was $2.64.

The target price for CALC Stock according to analyst rating is 16.00, with the highest price target at 20.00 and the lowest at 13.00. Analysts have a Strong Buy rating on CALC Stock overall.

The market cap of CALC is $35.7M.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

CALC has a total of 13 employees.